TEVA

20.52

0.20% 0.04

Handel nachbörslich: 20.50 -0.02 -0.10%

Teva Pharmaceutical Industries Ltd Adr (TEVA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt TEVA? Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$20.48

Offen:

$20.6

24-Stunden-Volumen:

10.62M

Relative Volume:

1.05

Marktkapitalisierung:

$23.53B

Einnahmen:

$16.70B

Nettoeinkommen (Verlust:

$-157.13M

KGV:

-141.91

EPS:

-0.1446

Netto-Cashflow:

$1.19B

1W Leistung:

+4.64%

1M Leistung:

+2.55%

6M Leistung:

+26.74%

1J Leistung:

+11.22%

1-Tages-Spanne:

$20.30

$20.88

1-Wochen-Bereich:

$19.23

$20.88

52-Wochen-Spanne:

$12.46

$22.80

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile

Firmenname

Teva Pharmaceutical Industries Ltd Adr

Sektor

Healthcare (1136)

Branche

Drug Manufacturers - Specialty & Generic (85)

Telefon

972 (3) 914-8213

Adresse

TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV

Mitarbeiter

35,686

Twitter

@TevaUSA

Nächster Verdiensttermin

2025-01-29

Neueste SEC-Einreichungen

TEVA's Discussions on Twitter

Vergleichen Sie TEVA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TEVA Teva Pharmaceutical Industries Ltd Adr	20.52	23.49B	16.70B	-157.13M	1.19B	-0.1446
ZTS Zoetis Inc	144.35	63.86B	9.39B	2.62B	2.22B	5.8121
TAK Takeda Pharmaceutical Co Adr	13.42	42.46B	29.96B	957.25M	4.77B	0.2956
HLN Haleon Plc Adr	9.38	41.28B	14.26B	1.98B	2.47B	0.4327
UTHR United Therapeutics Corp	438.66	19.18B	3.08B	1.24B	1.07B	25.61

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-06-06	Eingeleitet	Goldman	Buy
2025-05-28	Eingeleitet	Truist	Buy
2025-05-12	Hochstufung	JP Morgan	Neutral → Overweight
2024-07-10	Hochstufung	Argus	Hold → Buy
2024-03-08	Hochstufung	JP Morgan	Underweight → Neutral
2024-02-12	Hochstufung	Piper Sandler	Neutral → Overweight
2024-01-23	Hochstufung	Jefferies	Hold → Buy
2024-01-03	Hochstufung	Piper Sandler	Underweight → Neutral
2023-12-18	Eingeleitet	HSBC Securities	Buy
2023-11-27	Hochstufung	UBS	Neutral → Buy
2023-07-06	Hochstufung	UBS	Sell → Neutral
2023-05-25	Eingeleitet	Morgan Stanley	Equal-Weight
2023-05-18	Hochstufung	Evercore ISI	In-line → Outperform
2023-01-19	Herabstufung	Jefferies	Buy → Hold
2022-11-14	Herabstufung	JP Morgan	Neutral → Underweight
2022-11-04	Herabstufung	UBS	Neutral → Sell
2022-10-21	Fortgesetzt	Jefferies	Buy
2022-08-05	Hochstufung	BofA Securities	Neutral → Buy
2022-06-14	Fortgesetzt	UBS	Neutral
2022-05-17	Hochstufung	BofA Securities	Underperform → Neutral
2022-05-04	Herabstufung	Piper Sandler	Neutral → Underweight
2022-04-05	Hochstufung	Barclays	Equal Weight → Overweight
2022-03-25	Hochstufung	Bernstein	Mkt Perform → Outperform
2022-01-27	Herabstufung	Argus	Buy → Hold
2021-10-28	Herabstufung	Raymond James	Outperform → Mkt Perform
2021-05-04	Herabstufung	UBS	Buy → Neutral
2021-04-07	Fortgesetzt	RBC Capital Mkts	Sector Perform
2020-11-25	Eingeleitet	Oppenheimer	Perform
2020-08-06	Hochstufung	Barclays	Underweight → Equal Weight
2020-07-27	Fortgesetzt	Goldman	Neutral
2020-06-01	Hochstufung	SunTrust	Hold → Buy
2020-04-24	Fortgesetzt	Citigroup	Neutral
2020-04-06	Hochstufung	UBS	Neutral → Buy
2020-02-24	Herabstufung	Edward Jones	Hold → Sell
2019-11-12	Hochstufung	JP Morgan	Underweight → Neutral
2019-10-17	Hochstufung	Gabelli & Co	Hold → Buy
2019-08-07	Herabstufung	Evercore ISI	Outperform → In-line
2019-07-19	Eingeleitet	Wolfe Research	Peer Perform
2019-07-15	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2019-07-10	Fortgesetzt	Credit Suisse	Neutral
2019-07-05	Hochstufung	Argus	Hold → Buy
2019-06-11	Eingeleitet	Barclays	Underweight
2019-06-03	Hochstufung	Oppenheimer	Perform → Outperform
2019-05-30	Herabstufung	BofA/Merrill	Buy → Underperform
2019-05-28	Herabstufung	UBS	Buy → Neutral
2019-03-20	Eingeleitet	SunTrust	Hold
2019-03-07	Fortgesetzt	UBS	Buy

Alle ansehen

Teva Pharmaceutical Industries Ltd Adr Aktie (TEVA) Neueste Nachrichten

Nov 02, 2025

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November - Sahm

Nov 02, 2025

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05 - GlobeNewswire Inc.

Nov 02, 2025

Nov 01, 2025

Earnings call transcript: Teva’s Q2 2025 shows steady growth, stock rises - Investing.com

Nov 01, 2025

Oct 29, 2025

Teva Pharmaceutical Industries Ltd (TEVA) Stock Price, Trades & News - GuruFocus

Oct 29, 2025

Oct 28, 2025

eBay Upgraded, Meta Platforms Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Oct 28, 2025

Oct 26, 2025

ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView

Oct 26, 2025

Oct 25, 2025

TEVA Stock Price and Chart — VIE:TEVA - TradingView

Oct 25, 2025

Oct 20, 2025

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe - Sahm

Oct 20, 2025

Oct 15, 2025

SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures - Sahm

Oct 15, 2025

Oct 10, 2025

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder - Sahm

Oct 10, 2025

Oct 09, 2025

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Sahm

Oct 09, 2025

Oct 07, 2025

SciSparc And AutoMax Call Off Merger - Sahm

Oct 07, 2025

Oct 06, 2025

AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace

Oct 06, 2025

Sep 21, 2025

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction - Ariva

Sep 21, 2025

Sep 20, 2025

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed - Ariva

Sep 20, 2025

Sep 16, 2025

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting - Sahm

Sep 16, 2025

Sep 14, 2025

Bayforest Capital Ltd Sells 3,875 Shares of Teva Pharmaceutical Industries Ltd. $TEVA - Defense World

Sep 14, 2025

Sep 09, 2025

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy - Ariva

Sep 09, 2025

Teva Pharmaceutical ADR Trying To Close In On Key Technical Measure - inkl

Sep 09, 2025

Aug 29, 2025

Teva stock rises on launch of first generic weight loss GLP-1 drug - Investing.com Nigeria

Aug 29, 2025

Aug 28, 2025

Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN

Aug 28, 2025

Teva stock rises on launch of first generic weight loss GLP-1 drug By Investing.com - Investing.com South Africa

Aug 28, 2025

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss - Placera.se

Aug 28, 2025

Aug 21, 2025

TEVA Stock Price and Chart — TASE:TEVA - TradingView

Aug 21, 2025

Aug 18, 2025

Earnings call transcript: Teva’s Q2 2025 earnings beat fails to lift revenue - Investing.com

Aug 18, 2025

Aug 13, 2025

Teva (TEVA) Is Up 5.7% After FDA Approves AJOVY for Pediatric Migraine Prevention - Sahm

Aug 13, 2025

Aug 12, 2025